{"id":8672,"date":"2025-09-20T19:18:05","date_gmt":"2025-09-20T16:18:05","guid":{"rendered":"https:\/\/jordan-cardiac.org\/?p=8672"},"modified":"2025-09-20T19:18:05","modified_gmt":"2025-09-20T16:18:05","slug":"optimizing-hypertension-treatment-evidence-based-approaches-new-drugs","status":"publish","type":"post","link":"https:\/\/jordan-cardiac.org\/en\/optimizing-hypertension-treatment-evidence-based-approaches-new-drugs\/","title":{"rendered":"Optimizing Hypertension Treatment: Evidence-Based Approaches & New Drugs"},"content":{"rendered":"
Optimizing Hypertension Treatment: Evidence-Based Approaches & New Drugs<\/div>\n
<\/div>\n
Source: Cleveland Clinic Journal of Medicine \u2014 Review<\/div>\n
Date: September 2025 \u2022<\/div>\n
<\/div>\n
1. Big picture<\/span><\/div>\n
<\/div>\n
\u2022 BP control is still poor worldwide (~21% controlled).<\/span><\/div>\n
\u2022 Main causes: weak prevention policies, non-adherence, and therapeutic inertia (not intensifying when BP stays high).<\/span><\/div>\n
\u2022 Start with single-pill combinations when possible; they hit targets faster and keep BP controlled longer.<\/span><\/div>\n
<\/div>\n
2. First-line strategy (most adults)<\/span><\/div>\n
<\/div>\n
\u2022 Begin combination therapy:<\/span><\/div>\n
\u2022 ACEi\/ARB + CCB (preferred combo), or<\/span><\/div>\n
\u2022 *ACEi\/ARB + thiazide\/thiazide-like diuretic.<\/span><\/div>\n
\u2022 Use single-pill formats to improve adherence.<\/span><\/div>\n
<\/div>\n
3. Case 1 (new HTN, high CV risk: T2D, obesity) \u2014 What to start?<\/span><\/div>\n
<\/div>\n
\u2022 Best: ACEi\/ARB + CCB (amlodipine) in one pill + lifestyle.<\/span><\/div>\n
\u2022 Why not ACEi + thiazide as first choice?<\/span><\/div>\n
\u2022 ACCOMPLISH trial: benazepril+amlodipine reduced CV events more than benazepril+HCTZ despite similar BP.<\/span><\/div>\n
\u2022 Message: in high-risk patients, ACEi\/ARB + CCB is a strong, evidence-based start.<\/span><\/div>\n
<\/div>\n
4. Combination vs monotherapy<\/span><\/div>\n
<\/div>\n
\u2022 No head-to-head RCTs of \u201cstart mono then up-titrate\u201d vs \u201cstart combo,\u201d but multiple studies show:<\/span><\/div>\n
\u2022 Faster target attainment, better long-term control, greater BP fall with initial combo.<\/span><\/div>\n
<\/div>\n
5. Guideline harmony (US vs Europe)<\/span><\/div>\n
<\/div>\n
\u2022 Both: support initial combinations (low\/moderate doses).<\/span><\/div>\n
\u2022 US: especially for stage 2 HTN, BP \u226520\/10 above target, and many Black adults.<\/span><\/div>\n
\u2022 Europe: combo for most patients.<\/span><\/div>\n
\u2022 Practical nuance for many Black patients: thiazide\/CCB respond well; ACEi\/ARB monotherapy is often less effective.<\/span><\/div>\n
<\/div>\n
6. Case 2 (well-controlled on ACEi+HCTZ, post-MI) \u2014 Change anything?<\/span><\/div>\n
<\/div>\n
\u2022 No change: stay on current regimen if BP and risk are controlled.<\/span><\/div>\n
\u2022 Diuretic Comparison Project: switching HCTZ\u2192chlorthalidone did not improve major outcomes in already-controlled patients.<\/span><\/div>\n
<\/div>\n
7. Case 3 (uncontrolled on ARB+CCB) \u2014 What to add?<\/span><\/div>\n
<\/div>\n
\u2022 Add chlorthalidone (more potent and longer half-life than HCTZ).<\/span><\/div>\n
\u2022 Why not low-dose HCTZ? Less BP-lowering than chlorthalidone at comparable doses.<\/span><\/div>\n
\u2022 Monitor K+ and renal function (risk of hypokalaemia).<\/span><\/div>\n
<\/div>\n
8. Chlorthalidone vs HCTZ \u2014 quick facts<\/span><\/div>\n
<\/div>\n
\u2022 Half-life: chlorthalidone 40\u201360 h vs HCTZ 6\u20139 h.<\/span><\/div>\n
\u2022 Potency: chlorthalidone roughly 1.5\u20132\u00d7 HCTZ.<\/span><\/div>\n
\u2022 Safety: both can lower K+; chlorthalidone may do so more \u2192 monitor electrolytes.<\/span><\/div>\n
<\/div>\n
9. Case 4 (apparent resistant HTN on ACEi\/CCB\/thiazide) \u2014 First step<\/span><\/div>\n
<\/div>\n
\u2022 Tackle lifestyle + confirm adherence (salt restriction, weight, activity, simplify to single-pill combos, reminders).<\/span><\/div>\n
\u2022 Screen for obstructive sleep apnoea if suggested by history.<\/span><\/div>\n
\u2022 \u201cApparent\u201d resistance is often pseudo-resistance (non-adherence, white-coat, suboptimal regimen).<\/span><\/div>\n
<\/div>\n
10. Case 4 (true resistant HTN after optimisation) \u2014 Fourth drug<\/span><\/div>\n
<\/div>\n
\u2022 Add spironolactone (best 4th drug per PATHWAY-2; superior to doxazosin\/bisoprolol\/placebo).<\/span><\/div>\n
\u2022 If side effects or concern: consider eplerenone or indapamide as alternatives (clinical judgement).<\/span><\/div>\n
<\/div>\n
11. Case 5 (uncontrolled + hypokalaemia) \u2014 Think primary aldosteronism<\/span><\/div>\n
<\/div>\n
\u2022 Clues: HTN + low K+, sometimes metabolic alkalosis, even if on ACEi\/CCB\/thiazide.<\/span><\/div>\n
\u2022 Next step: measure plasma aldosterone and renin (or direct renin) \u2192 ARR screening.<\/span><\/div>\n
\u2022 If positive, confirm (e.g., saline infusion) and consider targeted therapy.<\/span><\/div>\n
<\/div>\n
12. Adherence \u2014 the quiet giant<\/span><\/div>\n
<\/div>\n
\u2022 Up to ~46% non-adherence in apparent resistant HTN (objective testing).<\/span><\/div>\n
\u2022 Improve by: single-pill combos, once-daily dosing, minimise cost, manage side effects, and use reminders\/pillboxes.<\/span><\/div>\n
<\/div>\n
13. New\/emerging therapies (for difficult HTN)<\/span><\/div>\n
<\/div>\n
\u2022 Aprocitentan (endothelin receptor antagonist): modest SBP reduction in resistant HTN; benefit sustained, relapse on withdrawal.<\/span><\/div>\n
\u2022 Aldosterone synthase inhibitors:<\/span><\/div>\n
\u2022 Lorundrostat: phase 2 shows ~8\u201311 mmHg SBP drop (dose-dependent).<\/span><\/div>\n
\u2022 Baxdrostat: dose-related SBP fall up to ~20 mmHg at 12 weeks; no adrenal insufficiency signals reported.<\/span><\/div>\n
\u2022 Zilebesiran (siRNA vs angiotensinogen): single SC injection; durable BP lowering (up to 24 weeks in early data); KARDIA-2 shows add-on benefit to standard drugs.<\/span><\/div>\n
\u2022 Tirzepatide (dual GIP\/GLP-1 RA): in obesity, weight loss drove ~7\u20138 mmHg SBP reduction; useful for metabolic syndrome\u2013related HTN.<\/span><\/div>\n
<\/div>\n
14. Practical \u201chow-to\u201d for the clinic<\/span><\/div>\n
<\/div>\n
\u2022 Start combo therapy early; prefer single-pill formats.<\/span><\/div>\n
\u2022 If uncontrolled on ARB\/ACEi + CCB, add chlorthalidone (or indapamide).<\/span><\/div>\n
\u2022 If still uncontrolled (true resistance): add spironolactone.<\/span><\/div>\n
\u2022 If hypokalaemia or resistant features: screen for primary aldosteronism.<\/span><\/div>\n
\u2022 Always address lifestyle + adherence before escalating.<\/span><\/div>\n
<\/div>\n
15. Safety & monitoring<\/span><\/div>\n
<\/div>\n
\u2022 Check K+ and creatinine after starting or changing ACEi\/ARB\/MRA (1\u20132 weeks), then every 3\u20136 months when stable.<\/span><\/div>\n
\u2022 Watch for hypokalaemia with thiazides\/chlorthalidone; hyperkalaemia with MRAs\/RAAS blockade.<\/span><\/div>\n
\u2022 Reassess every 3\u20136 months; escalate promptly if above target.<\/span><\/div>\n
<\/div>\n
https:\/\/www.ccjm.org\/content\/92\/9\/555?utm_source=chatgpt.com<\/a><\/div>\n
<\/div>\n","protected":false},"excerpt":{"rendered":"

Optimizing Hypertension Treatment: Evidence-Based Approaches & New Drugs Source: Cleveland Clinic Journal of Medicine \u2014 Review Date: September 2025 \u2022 1. Big picture \u2022 BP control is still poor worldwide (~21% controlled). \u2022 Main causes: weak prevention policies, non-adherence, and therapeutic inertia (not intensifying when BP stays high). \u2022 Start with single-pill combinations when possible; […]<\/p>\n","protected":false},"author":145,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-8672","post","type-post","status-publish","format-standard","hentry","category-uncategorized"],"_links":{"self":[{"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/posts\/8672","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/users\/145"}],"replies":[{"embeddable":true,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/comments?post=8672"}],"version-history":[{"count":1,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/posts\/8672\/revisions"}],"predecessor-version":[{"id":8673,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/posts\/8672\/revisions\/8673"}],"wp:attachment":[{"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/media?parent=8672"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/categories?post=8672"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/tags?post=8672"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}